Natera,Inc. (NASDAQ:NTRA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security
Holders.

On May23, 2017, Natera,Inc. (Natera) held its Annual Meeting of
Stockholders (the Annual Meeting). At the Annual Meeting, Nateras
stockholders voted on two proposals, each of which is described
in more detail in Nateras definitive proxy statement on Schedule
14A filed with the U.S. Securities and Exchange Commission on
April11, 2017.

Only stockholders of record as of the close of business on
March31, 2017, the record date for the Annual Meeting, were
entitled to vote at the Annual Meeting. As of the record date,
52,797,240 shares of Nateras common stock were outstanding and
entitled to vote at the Annual Meeting. In deciding all matters
at the Annual Meeting, each holder of common stock of Natera was
entitled to one vote for each share of common stock held as of
the close of business on the record date.

The tabulation of the stockholders votes on each proposal brought
before the Annual Meeting is as follows:

Proposal 1: The election of three directors to serve as
ClassII directors until the 2020 annual meeting of stockholders
and until his successor is duly elected and qualified:

Proposal 2: The ratification of the appointment of Ernst
Young LLP as Nateras independent registered public accounting
firm for the fiscal year ending December31, 2017:

About Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Natera, Inc. (NASDAQ:NTRA) Recent Trading Information

Natera, Inc. (NASDAQ:NTRA) closed its last trading session up +0.11 at 10.43 with 65,744 shares trading hands.